Latest Debiopharm Stories
One year after the initiation of Phase I, Debiopharm announced the start of clinical phase II for Debio 1450 in ABSSSI and presentation of new data at ECCMID LAUSANNE, Switzerland, April 23,
Debiopharm presents preclinical results for 2 anti-cancer targeted therapies Debio 1143 and Debio 1347 LAUSANNE, Switzerland, April 16, 2015 /PRNewswire/ -- Debiopharm International
DALLAS, March 18, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Hepatitis C - Pipeline Review, H1 2015" therapeutic market research report of 639 pages with latest updates,
RnRMarketResearch.com adds “Dyslipidemia – Pipeline Review, H1 2015” to its store.
- Novartis returns Alisporivir (DEB025) to Debiopharm Group(TM) including all rights for HCV and other indications - LAUSANNE, Switzerland, January 12, 2015 /PRNewswire/ --
Debio 1450, oral/IV FabI inhibitor active against all Staphylococcus species has received fast track designation for ABSSSI (acute bacterial skin and skin structure infections) LAUSANNE, Switzerland,
DALLAS, December 11, 2014 /PRNewswire/ -- RnRMarketResearch.com adds "Breast Cancer - Pipeline Review, H2 2014" and "Adrenocortical Carcinoma (Adrenal Cortex Cancer) -
LAUSANNE, Switzerland, November 18, 2014 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs
- An armed gangster.